

Read on web | Forward to a friend




### Fast and accurate neoantigen screening with dCODE Dextramer®

Is your research contributing to the development of future cancer immunotherapies? The identification of neoantigens triggering the immune response against cancer cells is crucial to increase the selectivity of neoantigen-based cancer vaccines.

Immudex is passionately committed to provide the scientific community with the best tools for immune monitoring. With dCODE Dextramer® you can identify and characterize neoantigen-specific T cells, providing clear information about neoantigen immunogenicity. The presence of a DNA oligo barcode on each dCODE Dextramer allows the simultaneous screening of tens to hundreds different neoantigens in one tumor sample. Combining dCODE Dextramer with Next Generation sequencing and single-cell multi-omics, it is possible to in-depth characterize the neoantigen-specific T-cell populations.

dCODE Dextramer technology offers a wide range of solutions to identify and characterize neoantigen-specific T cells based on TCR recognition.

[Read More About dCODE® Technology and T-cell Monitoring With the Power of Multiplexing](#)



Kind regards,

Sara Bursomanno, PhD  
*Product Manager*

**About Immudex:**

Immudex provides solutions for immune monitoring within cancer immunotherapy, transplantation, infectious disease, and autoimmunity. With an off-set in Immudex' proprietary Dextramer® and dCODE Dextramer® technologies, we develop and market research reagents and assay solutions, enabling researchers and clinicians to measure disease-specific immunity. GMP grade and diagnostic Dextramer reagents are available and currently in use within the USA and Europe. Under an agreement with the US Cancer Immunotherapy Consortium (CIC) and the European Cancer Immunotherapy Consortium (CIME), Immudex also provides MHC Multimer and Elispot proficiency panel services worldwide.

Immudex | [www.immudex.com](http://www.immudex.com) |

[Unregister](#)